MOUNTAIN LAKES, NEW JERSEY, USA | March 24, 2026
LiviWell, a women’s health innovation company, has announced U.S. FDA clearance for Livi, a first-of-its-kind post-intercourse vaginal care device designed to support intimate health by absorbing semen and vaginal fluids. This milestone introduces a new category in women’s health technology, addressing a long-overlooked area of post-sexual wellness with a clinically validated, user-friendly solution. The clearance underscores the growing importance of regulatory-backed femtech innovations that combine medical science, patient comfort, and real-world usability.
First-in-Class Innovation in Women’s Intimate Health
The newly cleared Livi device is a single-use, soft polyurethane foam insert, designed for vaginal use immediately after intercourse. Utilizing an applicator similar to a tampon, the device can be inserted quickly and works to absorb fluids within approximately 60 seconds, remaining effective for up to 15 minutes before removal. This innovative design directly addresses common post-intercourse concerns such as excess discharge, discomfort, and hygiene challenges, which have historically lacked targeted solutions. By introducing a simple, discreet, and clinically informed device, LiviWell is creating a new standard in post-intercourse care, expanding the scope of medical-grade feminine health products.
Clinical Rationale and Unmet Medical Need
From a clinical perspective, post-intercourse vaginal health has been an under-discussed area despite its relevance to millions of women globally. Research indicates that semen can disrupt vaginal pH balance, potentially leading to odor, irritation, and discomfort. The Livi device is designed to minimize these effects by removing residual fluids, thereby supporting the natural vaginal environment.
Advertisement
Experts highlight that increased awareness and innovation in this space are essential to addressing everyday yet medically relevant concerns. By aligning product development with clinical insights and patient-reported needs, LiviWell is bridging the gap between consumer wellness and evidence-based healthcare solutions.
Regulatory Milestone and Market Expansion
The FDA clearance of Livi represents a significant regulatory achievement, validating the product’s safety and intended use under medical device guidelines. This approval positions LiviWell within the rapidly growing femtech and medical device market, where demand for personalized and preventive healthcare solutions continues to rise. The company plans to launch Livi in the United States by May 2026, initially through online distribution channels, with expansion into retail markets expected in subsequent phases. This strategic rollout reflects the company’s vision to scale access to innovative women’s health solutions while maintaining compliance with regulatory and quality standards.
With FDA clearance secured, LiviWell is poised to redefine post-intercourse care by introducing a clinically validated, easy-to-use solution that enhances comfort, supports vaginal health, and brings greater attention to an important yet historically underserved aspect of women’s healthcare.
Source: LiviWell press release
